Ophthalmology6 Jul 2026
Xiidra Leads Most Patients to 'Clinically Meaningful' Eye Dryness ReductionRead article
Haematology5 Jul 2026
Liso-Cel Delivers Durable OS Benefit in R/R LBCL, Redefining TreatmentRead article
The Life Science Feed
Deep dives with clinicians, researchers, and industry leaders.
All episodes
Prostate Care: Balancing Immediate Relief with Long-Term Retreatment
Managing benign prostatic hyperplasia requires weighing rapid symptom improvement against the need for future interventions. Clinicians must consider patient preference and disease progression.
Breast NeoplasmsTucatinib Extends PFS in HER2-Positive Breast Cancer, No New Safety Signals
Tucatinib demonstrated extended progression-free survival in HER2-positive breast cancer with a consistent safety profile, reinforcing its role.
Solid TumorsWearable Devices Detect CAR-T CRS Hours Earlier, Improving Patient Outcomes
Wearable devices identify cytokine release syndrome (CRS) in CAR-T cell therapy recipients hours before clinical recognition, enabling earlier intervention and potentially reducing severe complications.
Bowhead Whale Longevity Genes Offer Clues for Cancer, Aging
8 min readBiomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
9 min readAlpha-Emitting Radioantibody Lowers PSA in CRPC
15 min readGenetic Test Identifies Breast Cancer Patients Who May Avoid Chemotherapy
12 min readGiredestrant Improves Breast Cancer Survival Regardless of Menopause
8 min read
Alcohol and Sugar: A Dual Metabolic Challenge for Patients
Patients consuming alcohol and high-sugar diets face a compounded metabolic risk, impacting liver function and glucose regulation. Clinicians must address both factors.
Liver CirrhosisEASL 2026 Forum: Enhancing Patient-Clinician Communication
The EASL 2026 Patient & Advocate Forum addresses critical gaps in patient-clinician communication and interprofessional collaboration.
Liver CirrhosisEASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
EASL 2026 will feature a Skills Learning Centre on liver and spleen elastography, highlighting its role in non-invasive fibrosis assessment.
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
7 min readMetabolic Dysfunction Associated Steatotic Liver Disease: An Overview
5 min readEASL 2026: Alcohol Policy Action Needed for Liver Disease
7 min readVariceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
8 min read
5D MRI Halves Scan Time for Congenital Heart Disease Imaging
A novel 5D MRI technique significantly reduces scan duration for congenital heart disease patients, improving image quality and patient experience.
Coronary Artery DiseaseHeat-Attributable CVD Years of Life Lost Projected to Rise Through 2050
Projections indicate a substantial increase in years of life lost due to cardiovascular disease attributable to heat exposure by 2050.
Heart FailureUniversal Heart Failure Definition Issued by Global Societies
Four major cardiology societies released a universal definition of heart failure, aiming to standardise diagnosis and research across the globe.
Novel Therapies Target Atherogenic Lp(a) Particle
11 min readAI-Assisted Fetal Echocardiography Improves Early CHD Detection
8 min readVitamin K2 Supplementation May Curb Coronary Calcification
12 min readClopidogrel and Omeprazole: Re-evaluating Concomitant Use Risk
7 min readHypotension Linked to Increased Alzheimer's Disease Risk
7 min read
Unapproved Retatrutide Use Challenges Clinicians
The off-label use of investigational retatrutide for weight management presents a significant challenge for clinicians, lacking robust long-term safety and efficacy data.
ObesityHaaland's 6,000-Calorie Diet: Performance Fuel or Health Risk?
Erling Haaland's reported 6,000-calorie daily diet, while fueling elite athletic performance, presents significant long-term health considerations for the general population.
Diabetes Mellitus Type 2Foundayo Confers Greater HbA1c Reduction Than Farxiga, Ozempic Pill in T2D
A new investigational therapy, Foundayo, demonstrated superior HbA1c reduction compared to both dapagliflozin and oral semaglutide in type 2 diabetes.
Elecoglipron Oral GLP-1 Reduces Glucose, Weight in Phase 2
11 min readGLP-1s for Addiction: Are We There Yet?
10 min readIsaacs Emphasizes 'Human Touch' in Diabetes Care Beyond Technology
9 min readMedically Tailored Meals Cut HbA1c More Than Subsidies in Type 2 Diabetes
11 min readGLP-1 Nonresponders Often Underserved by Inadequate Dosing, Poor Adherence
10 min read
TBI Linked Bidirectionally With Psychiatric and Neurologic Conditions
Traumatic brain injury (TBI) shows a two-way association with various psychiatric and neurologic conditions, increasing risk for both and being influenced by their presence.
Migraine DisordersMigraine Linked to Increased Vascular Dementia Odds in Observational Data
Observational studies indicate a consistent association between a history of migraine and elevated odds for developing vascular dementia later in life.
Alzheimer DiseaseCreatine Supplementation: Limited Evidence for Brain Health Benefits
Creatine supplementation shows inconsistent and largely unproven benefits for brain health in healthy adults, with some promise in specific populations facing metabolic stress.
New Parkinson's Drug Offers Sustained Levodopa Levels
9 min readML Model Predicts Epilepsy Onset in Depression, Depression in Epilepsy
9 min readHuntington's Disease Therapy Faces Regulatory Setbacks, Clinical Impact
10 min readCognitive Rehabilitation Eases Long-COVID Brain Fog
10 min readDopamine Agonists: A Fading Role in Parkinson's Treatment?
9 min readNew Regimen Confers 'Meaningful' Benefit in Aggressive Lymphoma
7 min readFDA Expands Casgevy for Sickle Cell in Children 2 Years and Older
8 min readMonoclonal Antibodies May Complicate Transfusion Testing
7 min readBlood Transfusion Safety: Pathogen Inactivation Reduces Transfusion-Transmitted Infections
7 min readChemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
8 min readPersonalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
7 min readMacrophages: Dual Role in Haematological Malignancies Explored
7 min readMolecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
7 min readITP Management: Bridging Clinician and Patient Perspectives
7 min readCLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
8 min read
Sleep Disruption and Fear Drive Chronic Rheumatic Pain
11 min readPodcast: Why Cheaper Humira Alternatives Face Resistance
ListenPodcast: Stopping Spinal Fusion Or Protecting The Gut?
ListenPodcast: Chasing Absolute Zero In Rheumatoid Arthritis
ListenPodcast: The ORAL Surveillance JAK Inhibitor Controversy
Listen
Air Embolism: Two Cases After Percutaneous Lung Biopsy
7 min readSingle Question May Flag Poor Quality Sleep in Patients
9 min readPembrolizumab Reduces Pulmonary AEs vs Chemotherapy in NSCLC
8 min readDupilumab Superior to Omalizumab in High-Biomarker Asthma
7 min readATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
8 min read
COVID Vaccine Efficacy in Children: A Review of Real-World Data
8 min readRifadin Syrup Under Review for Carcinogen Concerns
7 min readPublic Health Measures Significantly Reduced COVID-19 Incidence
8 min readData Integrity Concerns Raised in Pfizer's COVID-19 Vaccine Trial
7 min readVaccine Cold Chain Integrity Underpins Vaccine Security
8 min read
CAR T-Cell Therapy Nears Approval for Refractory Skin Diseases
7 min readTSW Controversy: Mitochondrial NAD Excess Identified, Diagnostic Clarity Emerges
9 min readPrior Authorization Delays Atopic Dermatitis Treatment Access
13 min readPatient-Reported Factors Redefine Alopecia Areata Severity
7 min readScalp Lesions: Rare Malignancies Mimic Benign Conditions
7 min readNearly 1 in 10 With Primary Biliary Cholangitis Have CKD
7 min readHalf of Older Adults With Metastatic Lung Cancer Receive No Systemic Treatment
8 min readESC Cardio-Oncology 2026: Key Sessions and Anticipated Focus Areas
Eptinezumab Improves Cognitive Symptoms in Migraine Patients
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
7 min readCurrent and Emerging Therapies for Pulmonary Tuberculosis
6 min readDown Syndrome: Skin Conditions Demand Dermatologists’ Attention
7 min read
Munich, DEAug 28 – 31UpcomingEASD 2026
Madrid, ESSep 9 – 12UpcomingERS 2026
Copenhagen, DKSep 12 – 15UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026
Vienna, ATOct 3 – 7UpcomingAHA 2026
Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026
Stockholm, SEJun 11 – 14PastEULAR 2026
London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30UpcomingESC 2026Munich, DEAug 28 – 31UpcomingEASD 2026Madrid, ESSep 9 – 12UpcomingERS 2026Copenhagen, DKSep 12 – 15UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026Vienna, ATOct 3 – 7UpcomingAHA 2026Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026Stockholm, SEJun 11 – 14PastEULAR 2026London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30
Optimising Transplant in Haemoglobinopathies: EHA 2026 Perspectives
Bispecific Antibodies Positioned in Relapsed Follicular Lymphoma
NDMM Treatment Optimisation: Communication Key to Individualisation
ANCA Vasculitis: Evolving Strategies Target Remission & Relapse Prevention
Inluriyo™ and Verzenio® Presentations at ASCO 2026
MASH Advanced Fibrosis: Experts Detail Unique Challenges at EASL 2026
Bronchoscopy Training: ATS 2026 Focuses on EBUS and Guided Techniques
YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
Real-World Data Confirms Proximal Complement Inhibition in PNH
ICI Dissemination Challenges Highlighted at ASCO 2026
Treat-to-Target in SLE: Balancing Burden, Benefit, and Risk
Outsmarting Shape-Shifting Lung Cancer Resistance
How Immunotherapy Unmasks Invisible Lung Cancer
PEAK Study Shows Novel Agent Improves PFS in Advanced GIST
Infection Prevention Critical in Hematological Malignancies
Right Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
ASCO 2026 May 30th Program Highlights: Immunotherapy Advances in Solid Tumors
Ventilator Management: Foundations for Bedside Implementation
Bispecific Antibodies Show Promise in Relapsed/Refractory Haematological Malignancies
CLL First-Line Treatment: BTK Inhibitors vs. Venetoclax Combinations
EASL 2026 Forum: Enhancing Patient-Clinician Communication
ITP Management: Bridging Clinician and Patient Perspectives
ASCO 2026 May 31st Program Highlights: Focus on Novel Immunotherapies
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
CLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
Rare Conditions: EHA 2026 Highlights Diagnostic Challenges
Contagion: Acute Respiratory Failure Cases Highlight Ventilator Management
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
ATS 2026: Lung Cancer Management Advances in Targeted Therapy
Desmopressin Dosing Refined for Central Diabetes Insipidus
XLH Management: Rheumatology Must Adapt at EULAR 2026
ILD Diagnosis and Management: A Practical ATS 2026 Update
Subcutaneous Immunotherapy Offers Alternative Administration at ASCO 2026
BCMA-Directed Therapies Show Efficacy in Relapsed/Refractory Multiple Myeloma
NDMM Treatment Advances: Quadruplet Regimens Show Efficacy
Triple Therapy Optimises COPD Outcomes at ATS 2026
Multiple Myeloma: Aligning Innovation with Clinical Practice at EHA 2026
A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
CD20-Targeted Therapies Remain Central to NHL Management
Autoantibodies: Hidden Drivers of Autoimmune Rheumatic Diseases
EASL 2026: PSC Therapies Advance Beyond Symptom Management
TRUQAP + Fulvestrant: 2L Option for HR+/HER2- aBC/mBC with PI3K-AKT Alterations
BTK Inhibitors in CLL: Evolving Landscape and Sequential Strategies
SLE Pathophysiology Advances Inform Future Precision Care at EULAR 2026
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
VEXAS Syndrome: Expert Consensus on Multidisciplinary Care at EULAR 2026
CPET Advances Refine Cardiopulmonary Disease Assessment at ATS 2026
Yoga Reduces Insomnia, Fatigue, Anxiety in Cancer Survivors
Myriad's Precise MRD™ Test Shows Ultra-Sensitive Detection at ASCO 2026
EULAR 2026: Psoriatic Disease Spectrum Highlights
Radiopharmaceutical Therapy: Improving Effectiveness, Access, and Safety
EGPA: Early Recognition & Targeted Intervention Improve Outcomes
Cancer Elimination at ASCO 2026: Aspirational Goals and Current Realities
EASL 2026 Consensus: AATD-Liver Disease Management Standardised
AATD: Aiming for AAT Restoration and Clinically Meaningful Endpoints
Immunotherapy and Targeted Therapy: New Data from ASCO 2026
Systemic Sclerosis: EULAR 2026 Highlights Diagnosis, Prognosis
IL-33's Dual Role in COPD: Inflammation and Mucus Dysfunction
Bispecific Antibodies in FL: EHA 2026 Explores Advancing Outcomes
JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD
MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
CAR T Therapy Shows Sustained Efficacy in Relapsed/Refractory Lymphoma
AML: Rethinking Intensive Therapy for Myelodysplasia-Related & Therapy-Related Subtypes
Avapritinib Improves Outcomes in Nonadvanced and Advanced Systemic Mastocytosis
HYRNUO® (Sevabertinib) Shows Efficacy in Advanced Solid Tumours
AI Foundation Models Enhance Diagnostic Insights in Oncology
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
ATS 2026: Bronchiectasis and NTM Pulmonary Disease Management
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
CLL: EHA 2026 to Address Unmet Needs in Treatment Selection
SpA Remission: Clinical Symptoms vs. Subclinical Inflammation at EULAR 2026
Obesity Management Improves Psoriatic Disease Outcomes
Low Alkaline Phosphatase: Recognizing Clinical Consequences
CAR T-Cell Therapy Guidelines Evolve for Lymphoma, Myeloma at EHA 2026
CD19+ B-Cell Targeting Shows Efficacy in IgG4-RD Management
Iron Status Clarifies Erythrocytosis, Symptoms in Polycythemia Vera
Biomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
Doctor-Patient Communication Improves Treatment Acceptance in Cancer
HTAN Decodes Tumor Evolution: Ecological Perspective at AACR2026
AML: Fitness, Not Age, Predicts IC Eligibility at EHA 2026
More Breast Cancer Patients Can Skip Axillary Dissection
Early ILD Recognition in SARD/SSc: Drivers of Progression and Workflow Solutions
ASCO 2026 May 29th Program Highlights: Novel Oncology Therapies
Hypercortisolism: Emerging Diagnostic and Management Insights
EULAR 2026: Earlier AxSpA Recognition Improves Disease Burden
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma
Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
HER2-Expressing Breast Cancer: Advancements in Targeted Therapies
Cancer Care Disparities Highlighted in Crisis, Displaced Populations
EHA 2026: Anticipating Advances in Haematological Malignancies
Rapid SLE Control Prevents Organ Damage: EULAR 2026 Focus
AML Treatment Strategies: Optimising Outcomes in a Complex Disease
EULAR 2026: Polymyalgia Rheumatica Guidelines Incorporate RWE
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
IDH1m AML: Ivosidenib Plus Azacitidine Improves OS by 12.5 Months
Evolving Infection Prevention in HSCT and Cellular Therapies
Sjögren’s Disease: Targeting Underlying Activity Beyond Symptoms
ASCO 2026 June 1st Program Highlights: Novel Immunotherapy Data
IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
Classic CAH: New Approaches to Glucocorticoid Dosing
Immune Drivers in Autoimmune Cytopenias Inform Patient Care
TLR7/8 Inhibition Offers New Lupus Perspective at EULAR 2026
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
Severe Asthma: Beyond Airway Focus in Treatment Decisions at ATS 2026
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
Bispecific Antibodies Efficacious in Multiple Myeloma with Renal Impairment
Pediatric Pulmonary Research Gaps Highlighted for Global Health
CELMoDs Show Promise in Relapsed/Refractory Multiple Myeloma
Early Intervention Crucial for Inflammatory Joint Disease, Osteoporosis
Epithelial Dysfunction: A Unified Target in Airway Disease Management
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
Tafasitamab-R-CHOP Boosts Frontline DLBCL Outcomes at ASCO 2026
B-Cell Dysregulation Targeted Upstream in Primary Sjögren Disease
TACE + Camrelizumab/Rivoceranib Improves OS in Unresectable HCC
Early Breast Cancer at ASCO 2026: Trials to Watch
AML: Fitness, Not Age, Predicts Intensive Chemotherapy Eligibility
RA Care: Navigating Treatment Choices at EULAR 2026
Fixed-Duration BCL-2 Combo Offers Time Off Treatment in 1L CLL
Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology
MAVEs Inform Variant Interpretation in Clinical Oncology Practice
CLL First-Line Therapy: Case-Based Insights from EHA 2026
DLBCL Management: Bispecific Antibodies as Emerging Therapeutic Option
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
HDV Management: EASL 2026 Highlights PegIFN-α as Standard
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
MCED Tests Show Promise for Earlier Cancer Detection at ASCO 2026
Personalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
CAR T: Speed and Reliability Critical for Patient Outcomes
DLBCL Treatment: Emerging Targeted Therapies at EHA 2026
Early AxSpA Diagnosis: Case-Based Discussion at EULAR 2026
Novel Approaches Address Multiple Myeloma Resistance at EHA 2026
CAR T in DLBCL: Optimising Patient Outcomes at EHA 2026
DNA Methylation Patterns Emerge as Sarcoma Biomarkers
EASL 2026: Alcohol Policy Action Needed for Liver Disease
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
Acute Respiratory Failure: Lifespan Phenotypes and Trajectories
MRD Status Guides First-Line Treatment Duration in Haematologic Malignancies
Bispecific Antibodies Show Promise in Relapsed/Refractory Multiple Myeloma
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease
MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
Caplacizumab Improves iTTP Outcomes in Real-World Settings
Pediatric Advanced Bronchoscopy: Precision in Airway Management
EULAR 2026: Methotrexate Remains Cornerstone in RA First-Line
Inflammation Drives Sickle Cell Disease Pathophysiology
Multidisciplinary Care Improves Spondyloarthritis Outcomes
AI Integration Improves Lung Cancer MDT Workflow at ATS 2026
AI Algorithms Enhance Pulmonary Disease Management at ATS 2026
Cancer Therapies Induce Lifespan Comorbidities: ACCR 2026 Review
Infection Prevention Critical in Hematological Malignancies
Early SLE Disease Control: Targeting IFN Pathway at EULAR 2026
Novel Biomarkers Improve Pediatric Solid Tumor Detection
Tile Radiation for Large Brain Mets: A New Approach at ASCO 2026
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
Salivary Galectin-9 Elevated in Primary Sjögren's, Lacks Disease Activity Correlation
ASCO 2026: Anticipating Advances in Oncology Treatment
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
ATS 2026: Ultrasound Education Advances for Clinical Practice
Korlym® Improves Cushing's Syndrome Symptoms in Patient Experience Data
Sarcoidosis: Current Understanding of Diagnosis and Management
Optimising PsA and axSpA Treatment: EULAR 2026 Focuses on Early Intervention
RA Patients Face Elevated Fracture Risk: EULAR 2026 Highlights
AI in Oncology: Practical Applications Transforming Cancer Care
Belantamab Mafodotin's Evolving Role in RRMM: EHA 2026 Insights
RA Treatment Optimisation: Applying Two Decades of Progress
Multidisciplinary Approach Improves Autoimmune ILD Management
MLVs: Dual Role in Brain Metastases Offers Therapeutic Targets
Myelofibrosis Management: Cytopenia Guides Treatment at EHA 2026
JAK Inhibitor Combinations Show Efficacy in Myelofibrosis at EHA 2026
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
AI, Wearables Transform Sleep Diagnostics: ATS 2026 Preview
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
Symptom Science Integration Improves Cancer Outcomes at ASCO 2026
Multimodal OSA Treatment: Nerve Stimulation, Surgery, Oral Appliances
FLT3 Inhibitors Improve AML Outcomes Pre- and Post-Transplant
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
Optimizing Frontline LR-MDS Treatment: EHA 2026 Data Review
Novel Approaches in R/R MM: Expert Perspectives from EHA 2026
BCMA Bispecifics Transition to Community Myeloma Care: EHA 2026
New Biologic Offers Option for Severe Eosinophilic Asthma
FLT3mut+ AML Outcomes: EHA 2026 Reviews Current Strategies
AI in Hematology: EHA 2026 Focuses on Practical, Ethical Integration
Novel Therapies Improve Outcomes Post-cBTKi in CLL at EHA 2026
Early Intervention in SLE/LN Reduces Long-Term Damage
CML Survivorship: Beyond Survival to Quality of Life
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
Immuno-Fibrotic Crosstalk: A New Target in Rheumatology
NK Cell Immunotherapy: Biology to Clinic at AACR 2026
New 2L+ Combination Therapy Shows Efficacy in RRMM Post-PI/IMiD
CD38 mAb Quad Therapy: Subcutaneous Dosing Reduces Burden
Lupus Management: Progress and Persistent Challenges at EULAR 2026
AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data
CAR T Cell Therapy Shows Promise in SLE and SSc Immune Reset
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension
CAR T Cell Therapy Shows Efficacy in Autoimmune Diseases at EULAR 2026
Macrophages: Dual Role in Haematological Malignancies Explored
Molecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
Immunological Insights Inform ILD & Transplant Outcomes
Oncodetect® MRD Test Shows Analytical Validity, Clinical Utility at ASCO
DLBCL Relapse: EHA 2026 Addresses Gaps in Treatment Strategy
DLBCL Treatment Sequencing: EHA 2026 Explores Current Therapies
Optimising Transplant in Haemoglobinopathies: EHA 2026 Perspectives
Bispecific Antibodies Positioned in Relapsed Follicular Lymphoma
NDMM Treatment Optimisation: Communication Key to Individualisation
ANCA Vasculitis: Evolving Strategies Target Remission & Relapse Prevention
Inluriyo™ and Verzenio® Presentations at ASCO 2026
MASH Advanced Fibrosis: Experts Detail Unique Challenges at EASL 2026
Bronchoscopy Training: ATS 2026 Focuses on EBUS and Guided Techniques
YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
Real-World Data Confirms Proximal Complement Inhibition in PNH
ICI Dissemination Challenges Highlighted at ASCO 2026
Treat-to-Target in SLE: Balancing Burden, Benefit, and Risk
Outsmarting Shape-Shifting Lung Cancer Resistance
How Immunotherapy Unmasks Invisible Lung Cancer
PEAK Study Shows Novel Agent Improves PFS in Advanced GIST
Infection Prevention Critical in Hematological Malignancies
Right Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
ASCO 2026 May 30th Program Highlights: Immunotherapy Advances in Solid Tumors
Ventilator Management: Foundations for Bedside Implementation
Bispecific Antibodies Show Promise in Relapsed/Refractory Haematological Malignancies
CLL First-Line Treatment: BTK Inhibitors vs. Venetoclax Combinations
EASL 2026 Forum: Enhancing Patient-Clinician Communication
ITP Management: Bridging Clinician and Patient Perspectives
ASCO 2026 May 31st Program Highlights: Focus on Novel Immunotherapies
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
CLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
Rare Conditions: EHA 2026 Highlights Diagnostic Challenges
Contagion: Acute Respiratory Failure Cases Highlight Ventilator Management
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
ATS 2026: Lung Cancer Management Advances in Targeted Therapy
Desmopressin Dosing Refined for Central Diabetes Insipidus
XLH Management: Rheumatology Must Adapt at EULAR 2026
ILD Diagnosis and Management: A Practical ATS 2026 Update
Subcutaneous Immunotherapy Offers Alternative Administration at ASCO 2026
BCMA-Directed Therapies Show Efficacy in Relapsed/Refractory Multiple Myeloma
NDMM Treatment Advances: Quadruplet Regimens Show Efficacy
Triple Therapy Optimises COPD Outcomes at ATS 2026
Multiple Myeloma: Aligning Innovation with Clinical Practice at EHA 2026
A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
CD20-Targeted Therapies Remain Central to NHL Management
Autoantibodies: Hidden Drivers of Autoimmune Rheumatic Diseases
EASL 2026: PSC Therapies Advance Beyond Symptom Management
TRUQAP + Fulvestrant: 2L Option for HR+/HER2- aBC/mBC with PI3K-AKT Alterations
BTK Inhibitors in CLL: Evolving Landscape and Sequential Strategies
SLE Pathophysiology Advances Inform Future Precision Care at EULAR 2026
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
VEXAS Syndrome: Expert Consensus on Multidisciplinary Care at EULAR 2026
CPET Advances Refine Cardiopulmonary Disease Assessment at ATS 2026
Yoga Reduces Insomnia, Fatigue, Anxiety in Cancer Survivors
Myriad's Precise MRD™ Test Shows Ultra-Sensitive Detection at ASCO 2026
EULAR 2026: Psoriatic Disease Spectrum Highlights
Radiopharmaceutical Therapy: Improving Effectiveness, Access, and Safety
EGPA: Early Recognition & Targeted Intervention Improve Outcomes
Cancer Elimination at ASCO 2026: Aspirational Goals and Current Realities
EASL 2026 Consensus: AATD-Liver Disease Management Standardised
AATD: Aiming for AAT Restoration and Clinically Meaningful Endpoints
Immunotherapy and Targeted Therapy: New Data from ASCO 2026
Systemic Sclerosis: EULAR 2026 Highlights Diagnosis, Prognosis
IL-33's Dual Role in COPD: Inflammation and Mucus Dysfunction
Bispecific Antibodies in FL: EHA 2026 Explores Advancing Outcomes
JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD
MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
CAR T Therapy Shows Sustained Efficacy in Relapsed/Refractory Lymphoma
AML: Rethinking Intensive Therapy for Myelodysplasia-Related & Therapy-Related Subtypes
Avapritinib Improves Outcomes in Nonadvanced and Advanced Systemic Mastocytosis
HYRNUO® (Sevabertinib) Shows Efficacy in Advanced Solid Tumours
AI Foundation Models Enhance Diagnostic Insights in Oncology
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
ATS 2026: Bronchiectasis and NTM Pulmonary Disease Management
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
CLL: EHA 2026 to Address Unmet Needs in Treatment Selection
SpA Remission: Clinical Symptoms vs. Subclinical Inflammation at EULAR 2026
Obesity Management Improves Psoriatic Disease Outcomes
Low Alkaline Phosphatase: Recognizing Clinical Consequences
CAR T-Cell Therapy Guidelines Evolve for Lymphoma, Myeloma at EHA 2026
CD19+ B-Cell Targeting Shows Efficacy in IgG4-RD Management
Iron Status Clarifies Erythrocytosis, Symptoms in Polycythemia Vera
Biomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
Doctor-Patient Communication Improves Treatment Acceptance in Cancer
HTAN Decodes Tumor Evolution: Ecological Perspective at AACR2026
AML: Fitness, Not Age, Predicts IC Eligibility at EHA 2026
More Breast Cancer Patients Can Skip Axillary Dissection
Early ILD Recognition in SARD/SSc: Drivers of Progression and Workflow Solutions
ASCO 2026 May 29th Program Highlights: Novel Oncology Therapies
Hypercortisolism: Emerging Diagnostic and Management Insights
EULAR 2026: Earlier AxSpA Recognition Improves Disease Burden
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma
Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
HER2-Expressing Breast Cancer: Advancements in Targeted Therapies
Cancer Care Disparities Highlighted in Crisis, Displaced Populations
EHA 2026: Anticipating Advances in Haematological Malignancies
Rapid SLE Control Prevents Organ Damage: EULAR 2026 Focus
AML Treatment Strategies: Optimising Outcomes in a Complex Disease
EULAR 2026: Polymyalgia Rheumatica Guidelines Incorporate RWE
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
IDH1m AML: Ivosidenib Plus Azacitidine Improves OS by 12.5 Months
Evolving Infection Prevention in HSCT and Cellular Therapies
Sjögren’s Disease: Targeting Underlying Activity Beyond Symptoms
ASCO 2026 June 1st Program Highlights: Novel Immunotherapy Data
IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
Classic CAH: New Approaches to Glucocorticoid Dosing
Immune Drivers in Autoimmune Cytopenias Inform Patient Care
TLR7/8 Inhibition Offers New Lupus Perspective at EULAR 2026
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
Severe Asthma: Beyond Airway Focus in Treatment Decisions at ATS 2026
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
Bispecific Antibodies Efficacious in Multiple Myeloma with Renal Impairment
Pediatric Pulmonary Research Gaps Highlighted for Global Health
CELMoDs Show Promise in Relapsed/Refractory Multiple Myeloma
Early Intervention Crucial for Inflammatory Joint Disease, Osteoporosis
Epithelial Dysfunction: A Unified Target in Airway Disease Management
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
Tafasitamab-R-CHOP Boosts Frontline DLBCL Outcomes at ASCO 2026
B-Cell Dysregulation Targeted Upstream in Primary Sjögren Disease
TACE + Camrelizumab/Rivoceranib Improves OS in Unresectable HCC
Early Breast Cancer at ASCO 2026: Trials to Watch
AML: Fitness, Not Age, Predicts Intensive Chemotherapy Eligibility
RA Care: Navigating Treatment Choices at EULAR 2026
Fixed-Duration BCL-2 Combo Offers Time Off Treatment in 1L CLL
Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology
MAVEs Inform Variant Interpretation in Clinical Oncology Practice
CLL First-Line Therapy: Case-Based Insights from EHA 2026
DLBCL Management: Bispecific Antibodies as Emerging Therapeutic Option
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
HDV Management: EASL 2026 Highlights PegIFN-α as Standard
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
MCED Tests Show Promise for Earlier Cancer Detection at ASCO 2026
Personalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
CAR T: Speed and Reliability Critical for Patient Outcomes
DLBCL Treatment: Emerging Targeted Therapies at EHA 2026
Early AxSpA Diagnosis: Case-Based Discussion at EULAR 2026
Novel Approaches Address Multiple Myeloma Resistance at EHA 2026
CAR T in DLBCL: Optimising Patient Outcomes at EHA 2026
DNA Methylation Patterns Emerge as Sarcoma Biomarkers
EASL 2026: Alcohol Policy Action Needed for Liver Disease
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
Acute Respiratory Failure: Lifespan Phenotypes and Trajectories
MRD Status Guides First-Line Treatment Duration in Haematologic Malignancies
Bispecific Antibodies Show Promise in Relapsed/Refractory Multiple Myeloma
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease
MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
Caplacizumab Improves iTTP Outcomes in Real-World Settings
Pediatric Advanced Bronchoscopy: Precision in Airway Management
EULAR 2026: Methotrexate Remains Cornerstone in RA First-Line
Inflammation Drives Sickle Cell Disease Pathophysiology
Multidisciplinary Care Improves Spondyloarthritis Outcomes
AI Integration Improves Lung Cancer MDT Workflow at ATS 2026
AI Algorithms Enhance Pulmonary Disease Management at ATS 2026
Cancer Therapies Induce Lifespan Comorbidities: ACCR 2026 Review
Infection Prevention Critical in Hematological Malignancies
Early SLE Disease Control: Targeting IFN Pathway at EULAR 2026
Novel Biomarkers Improve Pediatric Solid Tumor Detection
Tile Radiation for Large Brain Mets: A New Approach at ASCO 2026
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
Salivary Galectin-9 Elevated in Primary Sjögren's, Lacks Disease Activity Correlation
ASCO 2026: Anticipating Advances in Oncology Treatment
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
ATS 2026: Ultrasound Education Advances for Clinical Practice
Korlym® Improves Cushing's Syndrome Symptoms in Patient Experience Data
Sarcoidosis: Current Understanding of Diagnosis and Management
Optimising PsA and axSpA Treatment: EULAR 2026 Focuses on Early Intervention
RA Patients Face Elevated Fracture Risk: EULAR 2026 Highlights
AI in Oncology: Practical Applications Transforming Cancer Care
Belantamab Mafodotin's Evolving Role in RRMM: EHA 2026 Insights
RA Treatment Optimisation: Applying Two Decades of Progress
Multidisciplinary Approach Improves Autoimmune ILD Management
MLVs: Dual Role in Brain Metastases Offers Therapeutic Targets
Myelofibrosis Management: Cytopenia Guides Treatment at EHA 2026
JAK Inhibitor Combinations Show Efficacy in Myelofibrosis at EHA 2026
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
AI, Wearables Transform Sleep Diagnostics: ATS 2026 Preview
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
Symptom Science Integration Improves Cancer Outcomes at ASCO 2026
Multimodal OSA Treatment: Nerve Stimulation, Surgery, Oral Appliances
FLT3 Inhibitors Improve AML Outcomes Pre- and Post-Transplant
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
Optimizing Frontline LR-MDS Treatment: EHA 2026 Data Review
Novel Approaches in R/R MM: Expert Perspectives from EHA 2026
BCMA Bispecifics Transition to Community Myeloma Care: EHA 2026
New Biologic Offers Option for Severe Eosinophilic Asthma
FLT3mut+ AML Outcomes: EHA 2026 Reviews Current Strategies
AI in Hematology: EHA 2026 Focuses on Practical, Ethical Integration
Novel Therapies Improve Outcomes Post-cBTKi in CLL at EHA 2026
Early Intervention in SLE/LN Reduces Long-Term Damage
CML Survivorship: Beyond Survival to Quality of Life
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
Immuno-Fibrotic Crosstalk: A New Target in Rheumatology
NK Cell Immunotherapy: Biology to Clinic at AACR 2026
New 2L+ Combination Therapy Shows Efficacy in RRMM Post-PI/IMiD
CD38 mAb Quad Therapy: Subcutaneous Dosing Reduces Burden
Lupus Management: Progress and Persistent Challenges at EULAR 2026
AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data
CAR T Cell Therapy Shows Promise in SLE and SSc Immune Reset
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension
CAR T Cell Therapy Shows Efficacy in Autoimmune Diseases at EULAR 2026
Macrophages: Dual Role in Haematological Malignancies Explored
Molecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
Immunological Insights Inform ILD & Transplant Outcomes
Oncodetect® MRD Test Shows Analytical Validity, Clinical Utility at ASCO
DLBCL Relapse: EHA 2026 Addresses Gaps in Treatment Strategy
DLBCL Treatment Sequencing: EHA 2026 Explores Current Therapies
